title: The effect of short-term dutasteride intake in early-stage prostate cancer: analysis of 148 patients who underwent three-dimensional prostate mapping biopsy.
abstract: OBJECTIVE
  The effect of dutasteride on existing prostate cancer volume is largely unknown. In this study, we assessed the impact of dutasteride on tumor burden and Gleason score.
  
  
  METHODS
  A retrospective review of patients from our institution was performed, examining men interested in surveillance for prostate cancer, who underwent transperineal three-dimensional mapping (TP-3DM) biopsy within 3-6 months after their initial cancer diagnosis. The criteria to qualify for TP-3DM biopsy included prostate-specific antigen < 10 ng/mL, Gleason score ≤ 7, ≤ 2 positive cores out of 12. There were 2 cohorts of men--those who took dutasteride daily before the TP-3DM biopsy and those who did not receive any 5ARIs. Upstaging of prostate cancer diagnosis was defined as an increase in one or more positive cores or a change from unilateral to bilateral disease.
  
  
  RESULTS
  From 2006-2008, a cohort of 148 men underwent TP-3DM biopsy of the prostate. Ninety-one men received a treatment regime of dutasteride at least 3 months before TP-3DM biopsy. Fifty-seven men did not receive dutasteride or any other 5ARI. Approximately 74% of men who did not take dutasteride were upstaged and/or upgraded compared with 49.4% of men who received dutasteride (P = .0038).
  
  
  CONCLUSIONS
  We observed a 24.3% decrease in the proportion of upstaging and/or upgrading of prostate cancer in men who received dutasteride at least 3 months before 3D prostate TP-3DM biopsy. Thus, the effect of dutasteride on prostate cancer may have implications for its potential use as a secondary chemoprevention agent.
authors.affiliation: Department of Surgery, Division of Urology, University of Colorado Denver, Aurora, CO 80045, USA. al.barqawi@ucdenver.edu
authors.forename: Al B
authors.initials: AB
authors.lastname: Barqawi
authors.forename: Colin I
authors.initials: CI
authors.lastname: O'Donnell
authors.forename: Vassilis J
authors.initials: VJ
authors.lastname: Siomos
authors.forename: Amy H
authors.initials: AH
authors.lastname: Hou
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage*; D001378:Azasteroids / Q000008:administration & dosage*; D001707:Biopsy, Needle; D018890:Chemoprevention; D000068538:Dutasteride; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000517:prevention & control*; D055512:Tertiary Prevention; D018084:Ultrasonography, Interventional
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D000068538:Dutasteride